-
公开(公告)号：US20240360319A1
公开(公告)日：2024-10-31
申请号：US18767120
申请日：2024-07-09
Applicant: BioLegend, Inc.
IPC: C09B69/10 , C07C25/22 , C07C35/50 , C07C211/60 , C07C237/04 , C07D211/18 , C07D235/02 , C07D311/96 , C08G81/00 , C09B57/00 , G01N21/64
CPC classification number: C09B69/109 , C07C25/22 , C07C35/50 , C07C211/60 , C07C237/04 , C07D211/18 , C07D235/02 , C07D311/96 , C08G81/00 , C09B57/00 , C09B69/10 , G01N21/6428 , G01N2021/6439
Abstract: The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
-
公开(公告)号：US12091554B2
公开(公告)日：2024-09-17
申请号：US17469792
申请日：2021-09-08
Applicant: BIOLEGEND, INC.
IPC: C09B69/10 , C07C25/22 , C07C35/50 , C07C211/60 , C07C237/04 , C07D211/18 , C07D235/02 , C07D311/96 , C08G81/00 , C09B57/00 , G01N21/64
CPC classification number: C09B69/109 , C07C25/22 , C07C35/50 , C07C211/60 , C07C237/04 , C07D211/18 , C07D235/02 , C07D311/96 , C08G81/00 , C09B57/00 , C09B69/10 , G01N21/6428 , G01N2021/6439
Abstract: The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
-
公开(公告)号：US20240059654A1
公开(公告)日：2024-02-22
申请号：US18125961
申请日：2023-03-24
Applicant: The Regents of the University of California
Inventor： Michael E. Jung , Xiaohong Chen , Cun-Yu Wang , Jiong Li , Jie Zheng
IPC: C07D213/68 , A61P35/00 , C07C235/62 , C07C237/04 , C07C311/07 , C07D211/86 , C07D213/89 , C07D295/088 , C07D295/15 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07C237/38 , C07D213/50 , C07D213/55 , C07D213/40 , C07D213/06 , C07D213/38
CPC classification number: C07D213/68 , C07D213/38 , C07C235/62 , C07C237/04 , C07C311/07 , C07D211/86 , C07D213/89 , C07D295/088 , C07D295/15 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07C237/38 , C07D213/50 , C07D213/55 , C07D213/40 , C07D213/06 , A61P35/00
Abstract: The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
-
公开(公告)号：US11697639B2
公开(公告)日：2023-07-11
申请号：US16969005
申请日：2019-01-31
Applicant: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
Inventor： Jin Liu , Bowen Ke , Wensheng Zhang , Jun Yang , Lei Tang
IPC: C07D207/02 , C07D211/60 , C07C231/12 , C07C237/04 , C07D205/04 , C07D207/16 , C07D223/06 , C07D225/02
CPC classification number: C07D211/60 , C07C231/12 , C07C237/04 , C07D205/04 , C07D207/16 , C07D223/06 , C07D225/02
Abstract: A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.
-
公开(公告)号：US20190203052A1
公开(公告)日：2019-07-04
申请号：US16240024
申请日：2019-01-04
Applicant: BioLegend
CPC classification number: C09B69/109 , C07C25/22 , C07C35/50 , C07C211/60 , C07C237/04 , C07D211/18 , C07D235/02 , C07D311/96 , C08G81/00 , C09B57/00 , C09B69/10 , G01N21/6428 , G01N2021/6439
Abstract: The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays relying on fluorescence resonance energy transfer (FRET) mechanisms where two fluorophores are used.
-
Patent Agency Ranking
公开(公告)号：US10017459B2
公开(公告)日：2018-07-10
申请号：US15693905
申请日：2017-09-01
Applicant: Quadriga Biosciences, Inc.
Inventor： Bernd Jandeleit , Wolf-Nicolas Fischer , Kerry J. Koller , Gordon Ringold
IPC: A61K31/662 , C07C229/42 , A61K45/06 , A61K31/519 , A61K31/365 , A61K31/42 , A61K31/196 , C07F9/48 , C07C309/69 , A61K31/255 , A61K31/197 , C07C229/22 , C07C271/46 , A61K31/27 , C07C271/14 , C07C239/20 , C07C237/30 , C07C229/60 , A61K31/245 , C07C233/54 , C07D303/32 , A61K31/336 , A61K31/137 , C07C271/22 , C07C291/04 , C07C215/68 , C07C229/34 , C07C237/04 , C07D303/36
CPC classification number: C07C229/42 , A61K31/137 , A61K31/196 , A61K31/197 , A61K31/245 , A61K31/255 , A61K31/27 , A61K31/336 , A61K31/365 , A61K31/42 , A61K31/519 , A61K31/662 , A61K45/06 , C07B2200/07 , C07C215/68 , C07C229/22 , C07C229/34 , C07C229/60 , C07C233/54 , C07C237/04 , C07C237/30 , C07C239/20 , C07C271/14 , C07C271/22 , C07C271/46 , C07C291/04 , C07C309/69 , C07D303/32 , C07D303/36 , C07F9/4808
Abstract: β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
-
公开(公告)号：US10011562B2
公开(公告)日：2018-07-03
申请号：US15327962
申请日：2015-07-22
Applicant: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
Inventor： Lei Tang , Jin Liu , Wensheng Zhang , Jun Yang , Bowen Ke , Qinqin Yin
IPC: C07C237/04 , C07C237/16 , C07C231/12
CPC classification number: C07C237/04 , A61K31/167 , C07C219/04 , C07C231/12 , C07C237/16 , C07C237/20
Abstract: The present invention relates to long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled texture, and uses thereof. Said compounds show ultralong acting anaesthetic effect, and belong to N-diethylaminoacetyl-2,6-dimethylaniline compounds, having a structure according to formula (I). Said compounds may self-assemble into micelle or gel in an aqueous solvent, and exert an in vivo elongated local anesthetic actions. Local anesthesia and/or analgesic activity can last more than 72 hours. The biomaterials can self-assemble into micelles or gels in water and have local anesthetic effect, as well as can further be used as the coating of medicinal bioactive molecules for treatment of pain, itching and the like and/or the drug carriers, together with as pharmaceutical adjuvants for delivery system. Thus, said materials have a favorable perspective.
-
公开(公告)号：US20180078520A1
公开(公告)日：2018-03-22
申请号：US15563597
申请日：2016-01-12
Applicant: Mahmoud ELSOHLY , Waseem GUL , Mohammad Khalid
Inventor： Mahmoud ELSOHLY , Waseem GUL , Mohammad Khalid
IPC: A61K31/225 , C07D209/12 , C07C237/12 , C07C237/04 , A61K31/216 , C07C229/36 , C07C229/08 , A61K31/222 , C07C229/42
CPC classification number: A61K31/225 , A61K31/216 , A61K31/222 , C07C229/08 , C07C229/36 , C07C229/42 , C07C237/04 , C07C237/12 , C07D209/12
Abstract: The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
-
公开(公告)号：US09867830B2
公开(公告)日：2018-01-16
申请号：US15341784
申请日：2016-11-02
Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , COOPER HEALTH SYSTEM , SRI International
Inventor： Irving W. Wainer , Ruin Moaddel , Michel Bernier , Carlos A. Zarate , Marc C. Torjman , Michael E. Goldberg , Mary J. Tanga
IPC: A61K31/5375 , C07C225/20 , C07C237/04 , C07D295/108 , C07D295/112 , C07C229/48 , C07C237/20 , C07D295/15 , C07D295/155 , A61K31/137 , A61K31/165 , A61K31/222 , A61K31/24 , A61K31/265 , A61K31/4453
CPC classification number: A61K31/5375 , A61K31/137 , A61K31/165 , A61K31/222 , A61K31/24 , A61K31/265 , A61K31/4453 , C07B2200/07 , C07C225/20 , C07C229/48 , C07C237/04 , C07C237/20 , C07C2601/14 , C07C2601/16 , C07D295/108 , C07D295/112 , C07D295/15 , C07D295/155
Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
-
公开(公告)号：US09861599B2
公开(公告)日：2018-01-09
申请号：US15182851
申请日：2016-06-15
Applicant: QUADRIGA BIOSCIENCES, INC.
Inventor： Bernd Jandeleit , Wolf-Nicolas Fischer , Kerry J. Koller
IPC: C07F9/30 , C07C309/66 , C07C237/20 , C07C229/42 , C07C237/04 , C07F9/32 , C07F9/48 , C07C233/35 , C07C229/34 , C07C229/22 , C07C229/08 , C07C309/69 , C07C271/46 , C07C237/30 , A61K31/197 , A61K31/662 , C07C239/20 , A61K31/255 , A61K31/27
CPC classification number: A61K31/197 , A61K31/255 , A61K31/27 , A61K31/662 , C07C229/08 , C07C229/22 , C07C229/34 , C07C229/42 , C07C233/35 , C07C237/04 , C07C237/20 , C07C237/30 , C07C239/20 , C07C271/46 , C07C309/66 , C07C309/69 , C07F9/306 , C07F9/3264 , C07F9/48 , C07F9/4816
Abstract: β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
-
-
-
-
-
-
-
-
-
Search Results
400
records
(took 0.059 seconds)
